Welcome to our book review site go-pdf.online!
You may have to Search all our reviewed books and magazines, click the sign up button below to create a free account.
Drugs for HER-2-positive Breast Cancer
Growth factor receptors have long been known to drive malignant transformation and cancer progression. The epidermal growth factor receptor (EGFR, ErbB, HER) system is likely the best described membrane receptor tyrosine kinase family in malignant tumors. With implementation of the growth-inhibitory anti-HER-2 antibody trastuzumab (Herceptin) for the treatment of HER-2-positive advanced metastatic breast cancer, a new era has dawned in the therapy of this malignant disease. Unfortunately, trastuzumab-sensitive cancers invariably develop resistance to the antibody after some time. Recent clinical studies have revealed that these refractory tumors are still responsive to inhibition of the HER receptor family using dual HER-1/-2 inhibitors such as lapatinib (Tykerb/Tyverb). Moreover, a multiplicity of novel, improved irreversibly acting small molecular HER tyrosine kinase inhibitors are in the pipeline of many drug developing companies and are being evaluated in the clinical setting.
Systemic Lupus Erythematosus
More than 140 years ago, lupus erythematosus (LE) was recognized as a disease entity by clinicians working in the field of dermatology, which had only recently become an independent medical discipline. Soon after cutaneous lupus was first reported, it was realized that, apart from the skin, the disease could involve other organs and thus be systemic in nature. The latter observations were first made by MORITZ KApOSI [1], whose work has attracted renewed attention re cently and who succeeded FERDINAND VON HEBRA to the chair of dermatology at the Medical Faculty in Vienna. The early description of lupus erythematosus in both its cutaneous and systemic manifes tations was thus intimately associ...
Systemic Lupus Erythematosus
More than 140 years ago, lupus erythematosus (LE) was recognized as a disease entity by clinicians working in the field of dermatology, which had only recently become an independent medical discipline. Soon after cutaneous lupus was first reported, it was realized that, apart from the skin, the disease could involve other organs and thus be systemic in nature. The latter observations were first made by MORITZ KApOSI [1], whose work has attracted renewed attention re cently and who succeeded FERDINAND VON HEBRA to the chair of dermatology at the Medical Faculty in Vienna. The early description of lupus erythematosus in both its cutaneous and systemic manifes tations was thus intimately associ...
Mammacarcinom
Neu: Knapp gefaßter Therapie-Leitfaden mit den modernsten Forschungsergebnissen
Bronchuscarcinom
Das Bronchuscarcinom ist eines der epidemiologisch wichtigsten Probleme der Gegenwart. In den Ländern der Europäischen Union war das Bronchuscarcinom 1998 die häufigste Todesursache aufgrund einer malignen Erkrankung. Der dritte Band der Reihe "Onkologie heute" behandelt die verschiedenen Arten dieser Erkrankung und informiert über die möglichen Therapieformen. Die Autoren gehen auf die Entwicklungen der letzten Jahre, welche eine günstigere Prognose ermöglicht haben, ein und bieten einen kompletten Überblick über die derzeit gängigen Methoden und Verfahrensweisen. Diese und zukünftige Entwicklungen sollen letztendlich dazu führen, die Heilungschancen nach der Diagnose "Bronchuscarcinom" zu erhöhen. Onkologie heute Basierend auf dem aktuellsten Forschungsstand behandelt jeder Band dieser Reihe ein Organthema aus der Onkologie. Jährlich erscheinen zwei Bände.
Receptor Tyrosine Kinases: Structure, Functions and Role in Human Disease
Receptor Tyrosine Kinase: Structure, Functions and Role in Human Disease, for the first time, systematically covers the shared structural and functional features of the RTK family. Receptor Tyrosine Kinases (RTKs) play critical roles in embryogenesis, normal physiology and several diseases. And over the last decade they have become the Number 1 targets of cancer drugs. To be able to conduct fundamental research or to attempt to develop pharmacological agents able to enhance or intercept them, it is essential first to understand the evolutionary origin of the 58 RTKs and their roles in invertebrates and in humans, as well as downstream signaling pathways. The assembly of chapters is written by experts and underscores commonalities between and among the RTKs. It is an ideal companion volume to The Receptor Tyrosine Kinase: Families and Subfamilies, which proceeds, family by family through all of the specific subfamilies of RTKs, along with their unique landmarks.
Current Challenges in Vaccinology
We acknowledge the initiation and support of this Research Topic by the International Union of Immunological Societies (IUIS).
